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Like all other members of the herpesvirus family, the closely related human herpesviruses-6 and -7 (HHV-6,7) persist in their host throughout
life. In so doing, without exception, every member of the herpesvirus family has evolved mechanisms to avoid detection by the immune system. In
particular, human cytomegalovirus (HCMV), mouse cytomegalovirus (MCMV), human herpesvirus-8 (HHV-8), and herpes simplex virus (HSV)
all encode multiple proteins that interfere with proper MHC class I antigen presentation. The mechanisms employed by these viruses to effect
removal of MHC class I from the cell surface vary. The U21 open reading frame from HHV-7 diverts class I MHC molecules to an endolysosomal
compartment using an as-yet unknown mechanism. The two variants of HHV-6, HHV-6A and -6B, both possess a U21 open reading frame which
contain only ∼30% amino acid identity to the U21 sequence from HHV-7. Here we describe the characterization of the U21 gene products from
HHV-6A and HHV-6B. Like HHV-7 U21, both of the HHV-6 U21 molecules bind to and divert class I MHC molecules to an endolysosomal
compartment, effectively removing them from the cell surface, and providing a possible means of escape from immune detection.
© 2007 Elsevier Inc. All rights reserved.Keywords: Immune evasion; HHV-7; HHV-6; Human herpesvirus-7; Human herpesvirus-6; Class I MHC; U21Introduction
Human herpesvirus-6 (HHV-6) is a β-herpesvirus most
closely related to human herpesvirus-7 (HHV-7). HHV-6 and
HHV-7 possess almost entirely colinear genomes and share
many biological properties. Both viruses are T-lymphotropic,
but they can also infect other cell types, and both can cause
exanthem subitum (roseola), although HHV-6 is the most
common cause of this childhood disease (Zerr, 2006).
Approximately 90% of the population is seropositive for both
HHV-6 and HHV-7 by the age of 3. Primary infection with these
viruses occurs between 12 and 24 months with HHV-6, and
somewhat later (∼36 months) with HHV-7 (for a review, see
Dewhurst, 2004; Ward, 2005).
Despite their similarities, many of the clinical, epidemiolo-
gical, and biological features of these viruses differ. HHV-6 has⁎ Corresponding author. Fax: +1 414 456 6535.
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et al., 2005a,b). Of the two viruses, HHV-6 has been more
frequently and conclusively identified as the causative agent of
clinically serious disease, while less is known about the clinical
manifestations of HHV-7 (Ward, 2005). The two viruses also
use different receptors for cell entry: The receptor for HHV-6 is
the complement regulator CD46, while HHV-7 uses the T cell
co-receptor CD4 (Lusso et al., 1989, 1994; Santoro et al., 1999).
Two distinct variants of HHV-6 exist, HHV-6A and HHV-
6B, and although the genomes of the two variants are 90%
identical at the nucleotide level (the range among individual
genes is 31–98%), they differ significantly in their structure and
epidemiology (Braun et al., 1997; De Bolle et al., 2005a,b;
Dominguez et al., 1999). The vast majority of primary
infections in children are attributed to the HHV-6B variant
(Zerr et al., 2005). Approximately 40–50% of hematopoietic
stem cell transplant patients and∼32% of solid organ transplant
recipients develop HHV-6 infection several weeks after
transplantation, and 98% of these cases are due to the 6B
variant (Humar et al., 2002; Ljungman et al., 2000; Yoshikawa
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HHV-6B is also responsible for severe central nervous system
(CNS) disease (HHV-6-encephalitis) in transplant recipients
(for a detailed review, see Zerr, 2006). The clinical manifesta-
tions of HHV-6A remain ill-defined; although it is clearly both
neuro- and T-lymphotropic, it has not yet been etiologically
linked to any disease. HHV-6A contains 9 fewer open reading
frames (ORFs) than HHV-6B, and 9 more ORFs in HHV-6A do
not possess counterparts in HHV-6B (Dominguez et al., 1999;
Gompels et al., 1995).
Like all other herpesviruses, HHV-6 and -7 remain latent or
establish persistent infections. To do so, they must avoid
detection and elimination by the immune system. Viral immune
evasion strategies include restriction of viral gene expression,
infection at immunoprivileged sites, obstruction of antiviral
cytokine function, and interference with antigen presentation
(for a review, see Tortorella et al., 2000). Notably, all of the
herpesviruses thus far examined employ the latter strategy of
interfering with viral antigen presentation to cytotoxic T
lymphocytes (CTLs).
To present peptide antigens to CTLs, major histocompat-
ibility complex (MHC) class I heavy chains must form a
complex with the light chain, β2-microglobulin (β2-m), and
peptide to acquire a stable conformation. MHC class I-
associated peptides are generated by the proteasome in the
cytoplasm and are transported into the endoplasmic reticulum
(ER) by the TAP (transporter associated with antigen proces-
sing) transporter. Once in the ER, the peptides are loaded onto
MHC class I molecules. Stable class I/β2-m/peptide complexes
then traverse the Golgi en route to the cell surface, where they
can interact with CD8+ CTLs.
Herpesvirus gene products influence MHC class I antigen
presentation in numerous and diverse ways. Some herpesviral
proteins interfere with proteolysis of antigens or peptide
transport into the ER (Ahn et al., 1997; Hill et al., 1995;
Tomazin et al., 1996; York et al., 1994). Others retain or destroy
class I molecules (Ahn et al., 1996; Jones et al., 1996; Wiertz et
al., 1996; Ziegler et al., 1997), enhance the internalization of
class I molecules, or divert class I molecules to lysosomes for
degradation (Coscoy and Ganem, 2000; Hudson et al., 2001;
Ishido et al., 2000; Reusch et al., 1999; Stevenson et al., 2000).
Judging from the number and molecular diversity of these
strategies, the removal of MHC class I-peptide complexes from
the cell surface must be evolutionarily advantageous to these
viruses as a means of escaping immune detection.
HHV-7 encodes at least one such viral immunoevasin, U21.
HHV-7 U21 binds to class I MHC molecules in the ER and
diverts them to a lysosomal compartment, where they are
degraded, removing them from the cell surface (Hudson et al.,
2001). HHV-6A, but not HHV-6B, has also been shown to
remove class I MHC molecules from the cell surface of HHV-6-
infected cells (Hirata et al., 2001). The mechanism for this latter
downregulation, however, was not examined in detail (Hirata et
al., 2001). Here we demonstrate that the U21 open reading
frames encoded by HHV-6A and HHV-6B, which share only
∼30% identity with HHV-7 U21, function similarly to divert
class I molecules to the lysosomal compartment.Results
Amino acid sequence comparison of HHV-6A, -6B, and -7 U21
The sequence alignments of HHV-7, -6A, and -6B U21
molecules are presented in Figs. 1a and b. The nucleotide
sequences of HHV-6A and -6B U21 molecules are 90%
identical to each other, but HHV-6B U21 possesses an
additional 67-amino acid extension at its N-terminus (Fig. 1a).
We used the SignalP 3.0 server to predict the signal peptide
cleavage sites for the three U21s (Bendtsen et al., 2004). There
is a clear consensus for signal peptide cleavage after glycine at
position 14 in HHV-7 U21 that is conserved in all three U21
sequences. In the HHV-6B N-terminal extension, there is also a
weak consensus cleavage site between residues 33 and 34.
However, the deglycosylated protein products of both HHV-6A
and -6B U21 migrate at the same position in SDS–PAGE gels,
suggesting that the weak consensus site is not used, and that all
three U21s are cleaved at the same position (residue 14) in the
conserved consensus sequence (Fig. 6, lanes 6 and 8).
Of the four N-linked glycans utilized in HHV-7 U21, two are
conserved in HHV-6B U21, at positions 142 and 164, while
HHV-6A U21 conserves only one glycosylation site, at position
164. HHV-6B U21 appears to utilize one of these glycosylation
sites only partially, as it migrates as a doublet in SDS–PAGE
gels, and treatment with endoglycosidase F results in a
migratory shift commensurate with the trimming of both N-
linked glycans (Fig. 6, lanes 5 and 6).
The HHV-6 U21 molecules share only 30% identity with
HHV-7 U21. The cytoplasmic tails of HHV-6 and -7 U21 are
almost entirely dissimilar (Fig. 1b), but all three cytoplasmic
tails contain a conserved di-leucine or di-leucine-like (Ile-Ile)
sequence at position 412. We have previously demonstrated that
this Ile-Ile sequence may serve as an internalization signal for
HHV-7 U21 (Hudson et al., 2003).
HHV-6A U21 expression results in redistribution of class I
MHC molecules to lysosomes
In U373 astrocytoma cells stably transduced to express
HHV-7 U21, class I MHC molecules are located in a punctate
perinuclear location, consistent with the endolysosomal com-
partment, and class I MHC labeling of the plasma membrane is
greatly diminished (compare Fig. 2a with Fig. 2b; Hudson et al.,
2001). To determine whether HHV-6A U21 molecules could
also divert class I MHC molecules to a lysosomal compartment,
we performed immunofluorescence microscopy to examine the
intracellular localization of class I molecules in HHV-6 U21-
expressing cells. Expression of HHV-6A U21 in U373 cells
results in the dramatic redistribution of class I molecules to a
punctate perinuclear compartment (Fig. 2c).
HHV-6A U21 associates with properly folded class I MHC
molecules
To determine whether HHV-6 U21 associates with class I
molecules, we performed co-immunoprecipitation experiments,
Fig. 1. Sequence alignment of HHV-6A, -6B, and -7 U21. (a) Sequence comparison of HHV-6A and -6B U21. HHV-6A and -6B U21 are 90% identical at the amino acid level. HHV-6B U21 codes for an additional 67 N-
terminal amino acids. (b) Sequence comparison of HHV-6A and -7 U21. HHV-6A and -7 U21 share 30% amino acid identity. Identical amino acids are shaded yellow, and conserved residues are shaded green. The red
















Fig. 2. HHV-6 U21 diverts class I MHC molecules to a perinuclear location.
Control U373 cells (a), non-tagged HHV-7 U21-expressing U373 cells (b), or
non-tagged HHV-6A U21-expressing U373 cells (c) were labeled with W6/32,
an antibody directed against properly folded class I MHC molecules, and an
Alexa-488-conjugated secondary Ab.
Fig. 3. HHV-6A U21 associates with properly folded class l MHC molecules.
U373 control cells, HHV-7 U21-expressing cells, and HHV-6A U21-expressing
cells were labeled for 40 min with [35S]-methionine and class I molecules were
recovered with W6/32. HHV-6A U21, at 47 kDa, is noted, as is the 55-kDa
HHV-7 U21. The asterisks denote unknown high molecular weight polypeptides
(∼300–600 kDa) also recovered with W6/32.
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labeled HHV-6A U21-expressing U373 cells (Fig. 3). U21
molecules were recovered with class I MHC molecules both in
HHV-7 U21 cells and HHV-6A U21 cells (Fig. 3, lanes 1 and
3). The singly glycosylated HHV-6A U21 migrates at 46 kDa,
slightly slower than the class I MHC heavy chain molecules
(lane 3, marked 6A U21). Since an antibody directed against
HHV-6A U21 is not available, immunoblotting to confirm that
the slower migrating polypeptide in lane 3 is U21 is not
possible. However, further conformation that this ∼46-kDa
polypeptide corresponds to HHV-6 U21 was obtained by
examining the change in immunolocalization of class I MHC
molecules in these cells (Fig. 2c). Moreover, in addition to
HHV-6 U21, we also recover three polypeptides of high
molecular weight (300–600 kDa) in the α-class l MHC
immunoprecipitation from HHV-6 U21-expressing cells (lane
3, asterisks). These are not evident in immunoprecipitates from
control U373 cells nor from HHV-7 U21 cells, and theidentification of these polypeptides is in progress. In com-
parison, the 55-kDa HHV-7 U21 migrates more slowly,
reflecting the presence of its 4 N-linked glycans (lane 1;
Hudson et al., 2001).
The luminal domain of HHV-6A and -6B U21 binds to and
diverts class l MHC molecules to lysosomes
Because the interaction between U21 and class I molecules is
long-lasting, we originally hypothesized that HHV-7 U21 might
escort class I molecules to the lysosomal compartment, perhaps
by virtue of having a cytoplasmic sorting signal responsible for
signaling diversion of the U21-class I MHC protein complex
(Hudson et al., 2001). Surprisingly, however, deletion of the
transmembrane region and cytoplasmic tail of HHV-7 U21 did
not affect its ability to redistribute class I molecules to
lysosomes; thus, the lysosomal targeting information must be
contained within the lumenal domain of HHV-7 U21 (Hudson et
al., 2003). To examine whether the cytoplasmic tails are also
dispensable in HHV-6A and -6B U21, we replaced the
cytoplasmic tails of HHV-6A and -6B U21 molecules with a
C-terminal tandem tag consisting of a streptavidin binding
protein (SBP) domain and an HA epitope tag, separated by a
tobacco etch virus (TEV) site-specific protease cleavage site
(U21SBPHA) (Fig. 4c) (Call et al., 2002). We then examined
class l MHC localization in stable cell lines expressing HHV-6A
and -6B U21SBPHA. As shown in Fig. 4, both HHV-6A and -6B
U21SBPHA diverted class I molecules when their cytoplasmic
tails were replaced by the tag, demonstrating that, as for HHV-7
U21, the lumenal domains of HHV-6A and -6B U21 are
Fig. 4. The lumenal domain of HHV-6A and -6B U21 diverts class l MHC molecules to the lysosomal compartment. U373 cells, HHV-7, -6A, and -6B U21SBPHA-
expressing U373 cells were labeled with W6/32 and the lysosomal marker protein mAb, α-lamp2. The antibodies used in each panel are indicated. Arrows indicate
specific points of colocalization between W6/32 (class I MHC) and lamp2 labeling. (c) Schematic representation of the HHV-6A U21SBPHA construct expressed in
panels g–i. (f, i, l) Control U373 cells (green trace), HHV-7 U21SBPHA-expressing cells (orange), HHV-6A U21SBPHA-expressing cells (blue), or HHV-6B U21SBPHA-
expressing cells (purple) were incubated with the anti-PE HLA-A,B,C antibody directed against class l MHCmolecules and analyzed by flow cytometry. Control cells
incubated without anti-PE HLA-A,B,C antibody are indicated with the black trace.
129N.L. Glosson, A.W. Hudson / Virology 365 (2007) 125–135responsible for the diversion of class l MHC molecules (Fig. 4,
panels g and j).
To determine whether HHV-6A and -6B U21SBPHA-expres-
sing cells could divert class I MHC molecules to the lysosomal
compartment, we performed double-label immunofluorescence
microscopy using an antibody recognizing properly folded class
I molecules and an antibody directed against lamp2, a marker
for the lysosomal compartment. As shown in Fig. 4, HHV-7
U21SBPHA-expressing cells show a redistribution of class I
MHC molecules to a punctate perinuclear location that co-
localizes with lamp2 (Fig. 4, panels d and e). Likewise, HHV-
6A and -6B U21SBPHA-expressing cells also show a decrease inplasma membrane localization and intense punctate labeling of
a compartment that co-localizes with lamp2 (Fig. 4, panels g, h,
j, and k). Thus, like HHV-7 U21, the lumenal domain of HHV-
6A and -6B U21 is responsible for rerouting class I MHC
molecules to a lysosomal compartment, and replacement of the
cytoplasmic tail with this tandem epitope tag has no obvious
effect upon its association with class I MHC molecules, or its
ability to divert class I molecules to the lysosomal compartment.
Therefore, in subsequent experiments, cells expressing the
SBPHA-tagged versions of each U21 molecule are employed
when assessing U21's ability to divert class I molecules to the
lysosomal compartment. In the absence of an α-HHV-6 U21
Fig. 5. HHV-6A and -6B U21 are stabilized by lysosomal protease inhibitors. U373, HHV-7, -6A, and -6B U21SBPHA-expressing cells were pulse-labeled for 1 h and
chased for 0 or 6 h in the presence of leupeptin and Concanamycin A. Class I molecules were recovered with W6/32 and HA-tagged U21 molecules were recovered
from HHV-7, -6A, and -6B U21SBPHA-expressing cells with the anti-HA antibody 12CA5. Triangles denote polypeptides of high molecular weight that are recovered
in HHV-7 and -6B U21SBPHA-expressing cells. PhosphorImager quantitation of the fold difference in the intensities of U21 compared to the class I heavy chain, as
indicated by the downward arrow, are noted below the heavy chain in lanes 3–10. The magnitude of difference between the intensities of the class I heavy chain to U21
are denoted below the heavy chains in lanes 15–22, as indicated by the upward arrow, i.e. the class I heavy chain band in lane 8 is 3-fold more intense than the U21 it
co-precipitates.
Fig. 6. HHV-6B is partially glycosylated. U373, HHV-7, -6A, and -6B
U21SBPHA-expressing cells were labeled for 40 min with [
35S]-methionine and
class I molecules were recovered with W6/32. Immunoprecipitates were treated
with PNGase:F (+ lanes). Class I heavy chains (HC) and HHV-6 U21 molecules
+/− N-linked glycans are noted.
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U21.
HHV-6A and -6B U21 expression results in reduced class l
MHC on the plasma membrane
In principle, a successful viral immunoevasin should reduce
the number of class I MHC molecules available at the cell
surface for recognition by cytotoxic T cells. To examine the
presence of class I MHC molecules on the plasma membrane of
HHV-6B- and -6B U21SBPHA-expressing cells, we performed
flow cytometry experiments using an antibody directed against
the extracytoplasmic domain of HLA-A, -B, and -C. Cell
surface expression of class I MHC molecules is greatly reduced
in HHV-7 U21SBPHA-expressing cells, compared with that of
control U373 cells (Fig. 4f). Cell surface expression of class I
MHC molecules is also reduced in HHV-6A and -6B
U21SBPHA-expressing cells, but to a somewhat lesser extent
than in HHV-7 U21SBPHA-expressing cells (compare Figs. 4i
and l with Fig. 4f). This variation in cell surface class I
expression is in part attributable to differences in U21
expression levels, since subcloning of puromycin-resistant
cells resulted in the generation of some clonal cell lines in
which the entire population of cells exhibited a more
homogeneous reduction in surface expression of class I (data
not shown). However, the HHV-6B U21SBPHA cells shown in
panels j and l are a clonal cell line expressingHHV-6BU21SBPHA
at levels indistinguishable from that of the HHV-6A U21SBPHA-
expressing cells (see, e.g., Fig. 5, lanes 7 and 11; Fig. 6, lanes 5and 7; Fig. 7, lanes 3 and 4), suggesting that expression levels
do not account for the difference in cell surface class I MHC
expression seen between HHV-6A vs. HHV-6B U21SBPHA-
expressing cells.
Fig. 7. Immunoblot analysis of U21 and class I MHC heavy chain expression.
U373, HHV-7, -6A, and -6B U21SBPHA-expressing cell lysates were loaded on
SDS–polyacrylamide gels, transferred to nitrocellulose, and immunoblotted
with an α-HA mAb or the α-class I MHC heavy chain mAb HC10. The asterisk
denotes an SDS-resistant dimer of HHV-7 U21SBPHA, the circle denotes an α-
HA-reactive possible degradation product of HHV-7 U21SBPHA. HHV-7, -6A,
and -6B U21 as well as class I MHC heavy chains are indicated.
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If U21 acts as a chaperone to escort class l MHC molecules
to a lysosomal compartment for degradation, then inhibition of
lysosomal proteases should result in the stabilization of both
U21 and class I MHC molecules. To examine whether HHV-
6A and -6B U21 expression resulted in the degradation of
class l MHC molecules, we performed pulse-chase experi-
ments in the presence of leupeptin, a cysteine protease
inhibitor, and Concanamycin A, an inhibitor of the vacuolar
proton pump. Class I MHC molecules are stable for >6 h in
control U373 cells (Fig. 5, lanes 1 and 2). In cells expressing
U21SBPHA from either HHV-6A, -6B, or -7, however, neither
class I MHC nor U21 molecules are recoverable after 6 h of
chase (Fig. 5, lanes 4, 8, and 12). In the presence of lysosomal
protease inhibitors, both U21 and class I MHC molecules are
stabilized, indicating that in cells expressing U21, both U21
and class I MHC molecules are degraded by lysosomal
proteases (Fig. 5, lanes 6, 10, and 14). Of note, the tandem
SBPHA tag is approximately 40 amino acids longer than the
original cytoplasmic tail, resulting in slower migration in
SDS–PAGE than we observed for non-tagged HHV-6 U21
(Fig. 3).
We recover fewer labeled class I MHC molecules in α-HA
immunoprecipitations from HHV-6 U21SBPHA cells than from
HHV-7 U21SBPHA-expressing cells (Fig. 5, compare the ratio of
co-precipitating class I molecules to the immunoprecipitated
HA-tagged U21 in lanes 7 and 11 (U21:class I=∼12:1) to that
in lane 3 (U21:class I=∼2:1)). There are several possible
explanations for this observation: One possibility is that HHV-6
U21 may be expressed at higher levels than HHV-7 U21. This is
not the case; immunoblot analysis of total HA immunoreactivityin the cell lysates demonstrates that HHV-7 U21 is expressed at
roughly 4-fold higher levels than HHV-6 U21 molecules (Fig. 7,
lane 2). Alternatively, this observation could also be explained
by differences in the rates of degradation, synthesis, and/or
trafficking of class I MHC or U21 molecules. However, even
when we inhibit lysosomal degradation with lysosomal protease
inhibitors, the ratio of [35S]-labeled class I MHC molecules
recovered with HHV-6 U21 appears unchanged (Fig. 5,
compare lanes 10 ((U21:class I=∼11:1) with lane 6 (U21:
class I=∼2:1)), suggesting that a difference in stability does not
explain the observation that fewer labeled class I MHC
molecules are recovered with HHV-6 U21. The remaining
possibility is consistent with the idea that HHV-6 U21
molecules may associate less efficiently with class I MHC
molecules than does HHV-7 U21.
The reciprocal immunoprecipitations yield similar informa-
tion: When class I MHC molecules were recovered from the
same HHV-7 U21SBPHA and HHV-6B U21SBPHA lysates, the
ratio of class I heavy chains to the coprecipitating U21SBPHA is
more equivalent for HHV-7 U21 than for HHV-6B U21
(compare lanes 15, 17, or 18 (class I:U21=∼1:1) to lanes 19,
21, or 22 (class I:U21=∼3:1)).
This set of reciprocal immunoprecipitations, using W6/32 to
recover class I and the U21SBPHA molecules that associate with
it, also suggests that U21 likely remains in complex with the
class I molecules that are diverted to the lysosomal compart-
ment: When U21 molecules are recovered, virtually all of the
U21 and the class I molecules associated with it were degraded
after 6 h of chase (Fig. 5, lanes 4, 8, and 12). However, in
immunoprecipitations with W6/32, all of the U21 associating
with class I molecules is degraded, yet a large proportion of
class I MHC still remains, suggesting that the class I MHC
molecules not bound by U21 are not redirected to the lysosomal
compartment (lanes 16 and 20).
Although all samples were normalized for TCA-precipitable
counts before immunoprecipitating, in this experiment we note
that for some reason the amount of radioactivity in the HHV-7
U21 IPs in the absence of lysosomal protease inhibitors (lanes
15 and 16) appears uniformly reduced compared to other
samples. The problem does not affect interpretation of the
experiment.
Of note, we also recover an ∼140-kDa coprecipitating
polypeptide with HHV-6B U21SBPHA that is stabilized in the
presence of lysosomal protease inhibitors (Fig. 5, lanes 9–12,
gray arrowhead). This polypeptide is not recovered with HHV-7
U21SBPHA, nor is it apparent in HHV-6A U21SBPHA immune
complexes. Similarly, from HHV-7 U21SBPHA-expressing cells,
we recover a polypeptide of ∼210 kDa, which is stabilized by
lysosomal protease inhibitors (black arrowhead). Both of these
higher molecular weight polypeptides are also recovered upon
immunoprecipitation of the complex with the W6/32 anti-class I
MHC antibody (Fig. 6, lanes 3 and 5), and both are endo-
glycosidase sensitive (Fig. 6, lanes 4 and 6). In fact, upon
PNGase:F digestion, the HHV-7 U21-associated 210-kDa band
and the HHV-6B U21-associated 140-kDa band are reduced to
polypeptides that migrate similarly, both at ∼130 kDa in SDS–
PAGE gels (Fig. 6, lanes 4 and 6, open square). Based on their
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cosidase F, we surmised these slower-migrating polypeptides
to be SDS-resistant multimers of the U21 molecules. An α-HA
immunoblot also confirmed the presence of high molecular
weight α-HA-reactive polypeptides (Fig. 7, lane 2). Treatment
of the cells with the alkylating agent N-ethyl maleimide
(NEM) before lysis altogether abolished the appearance of
these higher molecular weight polypeptides, suggesting that
they are indeed dimers of U21 that form post-lysis (data not
shown).
Steady-state levels of class I MHC heavy chain molecules are
reduced in U21-expressing cells
To examine the steady-state expression levels of the
U21SBPHA and class I MHC molecules, we performed
immunoblot analysis on NP-40 lysates of U21SBPHA-transduced
U373 cells. To ensure that all immunoreactive bands would
appear within linear range of detection, we loaded half as much
HHV-7 U21SBPHA cell lysate as U373, and HHV-6A and -6B
U21SBPHA lysates. HHV-7 U21SBPHA, with its four N-linked
glycans and complex-type oligosaccharide modifications,
appears at steady state to be present at 4- to 8-fold higher
levels than either HHV-6A or -6B U21 (Fig. 7, lane 2). As
discussed earlier, an α-HA-reactive polypeptide of approxi-
mately twice the size of HHV-7 U21SBPHA is present in these
lysates (Fig. 7, lane 2, asterisk), and we believe this to be an
SDS-resistant dimer of U21 that forms post-lysis. It is usually
visible in HHV-6B U21 immunoprecipitations as well, but it is
not apparent in this immunoblot at this exposure (see Figs. 5 and
6). Additionally, we observe an α-HA-reactive degradation
product of HHV-7 U21SBPHA in these lysates (Fig. 7, lane 2).
This degradation product must necessarily contain the C-
terminal SBPHA tag and transmembrane domain, and interest-
ingly, since we do not recover this product in class I MHC
immunoprecipitation experiments, this fragment must exclude a
portion of the lumenal domain necessary for binding to class I
MHCmolecules (Fig. 6, lane 3). As discussed previously, HHV-
6B U21 migrates as a doublet due to its partial use of a second
glycosylation site (Fig. 7, lane 3). Steady-state expression levels
of HHV-6A and HHV-6B U21 appear similar (Fig. 7, lanes 3
and 4).
Discussion
Here we describe two new viral immunoevasins from HHV-6
that share homology with and function similarly to the U21
immunoevasin from HHV-7. Although HHV-6A and -6B U21
proteins share only 30% amino acid identity with HHV-7 U21,
both HHV-6A and HHV-6B encode U21 proteins that, like U21
from HHV-7, can divert class I MHC molecules to a lysosomal
compartment. From the information we have gathered, we may
now employ sequence alignment to infer possible regions of the
U21 molecule that might be important either in its association
with class I MHC molecules, or in its association with the
cellular mechanism for lysosomal sorting that is hijacked by
these viral proteins.The cytoplasmic tails of the HHV-6 U21 molecules possess
almost no homology to the cytoplasmic tail of HHV-7 U21, with
the exception of a conserved di-leucine sequence (Fig. 1b). For
HHV-7 U21, we originally hypothesized that its cytoplasmic tail
might contain lysosomal targeting information to divert the
U21-class I MHC complex to the lysosomal compartment. To
test this hypothesis, we replaced the cytoplasmic tail of the
plasma membrane-localized CD4 molecule with that of HHV-7
U21. We demonstrated that the cytoplasmic tail of U21 was
sufficient to confer intracellular localization upon this chimera,
and that this conserved di-leucine-like sequence was respon-
sible for intracellular sequestration. Interestingly, the intracel-
lular localization of this CD4-U21 chimera was not lysosomal;
rather, it appeared to be localized to the Golgi (Hudson et al.,
2003). And, as we have discussed, the cytoplasmic tail of U21 is
not necessary for its ability to redirect class I MHC molecules to
the lysosomal compartment. However, the conservation of this
di-leucine motif in the cytoplasmic tails of HHV-6A, -6B, and
-7 U21 molecules, together with the clear demonstration that the
di-leucine-like sequence in HHV-7 U21 acts as a potent
intracellular sequestration motif, suggests that the cytoplasmic
tails of these molecules may not be entirely without function.
We have not yet pursued this possibility further with HHV-6A
and -6B U21, since it is clear that the cytoplasmic tail of U21 is
dispensable for U21-mediated diversion of class I MHC
molecules to lysosomes. However, it is worth noting that the
tailless and hybrid HHV-7 U21SBPHA molecules may be slightly
less efficient at preventing class I molecules from arriving at the
cell surface, and we hypothesize that this internalization signal
may act redundantly to remove any U21-class I complexes that
do arrive at the cell surface in error (data not shown; Hudson et
al., 2003).
In examining the abilities of the HHV-6A, -6B, and -7 U21
molecules to divert class I MHC molecules to lysosomes, we
show representative immunofluorescence of single cells (Fig. 4,
panels d, g, j, arrowheads), as well as flow cytometric analysis
of the population cells engineered to express the various U21
molecules (panels f, i, l). We consistently observe less class I
MHC immunoreactivity at the cell surface in HHV-7
U21SBPHA-expressing cells than in either HHV-6A or -6B
U21SBPHA cells, suggesting that HHV-7 U21 may be a more
effective immunoevasin. It remains possible, however, that U21
from HHV-7 appears more efficient because its expression level
of HHV-7 U21SBPHA in the cells is ∼4- to 8-fold higher (Figs.
5–7). We have not obtained HHV-6A or -6B U21 cell lines that
express levels of U21 equal to that expressed in our HHV-7
U21SBPHA cells. It is also possible that replacement of the
cytoplasmic tails of the U21 molecules with the SBPHA tag
might differentially affect their function. However, without
specific antisera directed against HHV-6A and -6B U21, we
must utilize tagged molecules so that we may confirm the
expression of these molecules in cells.
We also demonstrate that HHV-6A U21 appears to be more
effective than HHV-6B U21 at removing class I molecules from
the cell surface (Fig. 4, panels g–l). In this instance, the
expression levels of HHV-6A and -6B U21SBPHA in the cells are
similar and cannot account for the observed variation in class I
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suggest that, although HHV-6B U21 shares 89% amino acid
identity to HHV-6A U21, it may be a less-effective immunoe-
vasin than the U21 from HHV-6A. Interestingly, Hirata et al.
(2001) examined the cell-surface expression of class I MHC
molecules in the context of HHV-6A and -6B virus infection
and found that class I MHC molecules were downregulated
from HHV-6A but not HHV-6B-infected cells. Taken together,
these results suggest that U21 provides a mechanism to remove
class I MHC molecules from the cell surface in HHV-6A-
infected cells. Although HHV-6B U21 can clearly bind to and
divert class I MHC molecules (Figs. 4–6), on the whole, its role
in this process in the cell and during virus infection appears
reduced, in comparison to HHV-6A.
Our working model for U21-mediated diversion of class I
MHC molecules incorporates the following observations: U21
binds to class I molecules in the ER, soon after both molecules
are synthesized. It accompanies class I at least as far as the trans-
Golgi (Hudson et al., 2001), thus we hypothesize that U21 acts
as an escort to divert class I molecules to the lysosomal
compartment. Since the interaction between U21 and class I
molecules is lasting (Hudson et al., 2001), and both U21 and
class I molecules are stabilized in the presence of lysosomal
protease inhibitors (Fig. 5), we favor the idea that the two
molecules travel together to the lysosomal compartment by an
as-yet unknown mechanism.
Is U21 the only mechanism employed by HHV-6 to remove
class I molecules from the cell surface, or, like the other β-
herpesviruses, are there also multiple mechanisms encoded by
HHV-6 to impair CTL recognition of virus-infected cells? If not,
how does HHV-6B, which appears to have a less effective U21,
survive in the face of a fully functioning immune system?
Interestingly, the most closely related viruses to HHV-6 and
HHV-7, the β-herpesviruses HCMV and MCMV, each encode
at least four different immunoevasins that affect the cell surface
localization of class I MHC molecules (Tortorella et al., 2000).
In HCMV, these gene products may have arisen by gene
duplication of a common ancestor; US2, 3, 6, and 11, are all
encoded within the US region of the genome, and all of them
share sequence and/or structural homology with one another
(Gewurz et al., 2001; Jones and Muzithras, 1992; Jones et al.,
1991). Of these gene products, US2 and US11 function
similarly to cause the retrotranslocation of class I MHC
molecules. In addition to US2, 3, 6, and 11, the US region of
the genome encodes several other gene products, US7, 8, 9, and
10, which are all predicted to contain structurally similar Ig
folds (Gewurz et al., 2001), and some (US8, 9, and 11) share as
much as 30% sequence identity. However, no function, other
than the ability to bind to class I, has been attributed to these
viral glycoproteins (Furman et al., 2002; Huber et al., 2002;
Jones and Muzithras, 1992; Jones et al., 1991; Tirabassi and
Ploegh, 2002). Can a virus truly afford to faithfully encode a
protein that does not abet its infectivity or growth, or are these
herpesvirus proteins serving other, as-yet unidentified func-
tions? The data we report here describes the function of two new
viral immunoevasins, the U21 molecules from HHV-6A and
HHV-6B. Although the HHV-6 U21s appear to functionsimilarly to HHV-7 U21, the U21 from HHV-6B, in particular,
does not appear to remove class I MHC molecules from the cell
surface as efficiently as its counterpart from HHV-7, calling in
to question whether, like HCMV and MCMV, HHV-6 and -7
may encode more than one mechanism devoted to removing
class I MHC molecules from the cell surface to escape detection
by cytotoxic T lymphocytes.
Materials and methods
Cell lines
U373 astrocytoma cells were cultured in Dulbecco's
modified Eagle medium (DMEM)–5% fetal bovine serum–
5% newborn calf serum in the presence or absence of
puromycin [375 ng/ml final] (Sigma-Aldrich, St. Louis, MO,
USA) or geneticin (G418) [400 ng/ml final] (Gibco, Grand
Island, NY, USA). Expression of viral proteins in cells was
carried out via retrovirus-mediated gene transfer, using the
vector pLNCX, which carries the selectable marker for
neomycin resistance. U373 astrocytoma cells were infected
with retroviruses encoding HHV-6A U21, or HHV-6A or -6B
U21 with a streptavidin binding protein (SBP) domain and an
HA epitope tag separated by a tobacco etch virus (TEV)
protease cleavage site (SBPHA), as described by Hudson et al.
(2001, 2003). Stably expressing cell clones were isolated after
selection in G418.
Antibodies
W6/32 is a monoclonal antibody (mAb) that recognizes
assembled, β2m-associated HLA-A, -B, or -C molecules which
was generously provided by Dr. Hidde Ploegh (Whitehead
Institute, Cambridge, MA) (Barnstable et al., 1978). α-Giantin
was purchased from Covance (San Diego, CA). Immunofluor-
escence studies were performed either with a polyclonal
antibody directed against the HA epitope tag (Affinity
BioReagents, Golden, CO) or the α-HA mAb 12CA5. α-HA
immunoprecipitation experiments were performed with the
12CA5 mAb. Alexa-Fluor 488 and 594-conjugated secondary
antibodies were purchased from Molecular Probes, Eugene,
OR, USA. In some instances, Alexa 594-conjugated FAb
fragments (Zenon, Molecular Probes) were used to label lamp2
mAbs. α-lamp2 MAb was the generous gift of Dr. T. August
(Johns Hopkins Medical School, Baltimore, MD). A phycoer-
ythrin (PE)-conjugated anti-HLA-A,B,C mAb (BD Pharmin-
gen, San Jose, CA) was used in flow cytometry experiments.
Pulse-chase experiments
Cells were detached with trypsin and incubated with
methionine- and cysteine-free DMEM for 30 min at 37 °C.
The cells were labeled with 500 μCi/ml of [35S]-Express label
(1175 Ci/mmol; PerkinElmer, Boston, MA) at 37 °C for the
indicated times and chased with complete DMEM supplemen-
ted with non-radiolabeled methionine and cysteine to a final
concentration of 1 mM at 37 °C. Cells were lysed in Nonidet P-
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MgCl2, 150 mM NaCl). Lysates were centrifuged for 5–10 min
at 16,000×g at 4 °C in an Eppendorf centrifuge to pellet nuclei
and debris and precleared with standardized Pansorbin
(Staphylococcus aureus) cells (EMD Biosciences, Inc., San
Diego, CA) and 3 μl of normal mouse serum, followed by
immunoprecipitation with specific antiserum and protein A
agarose (RepliGen Corporation, Waltham, MA, USA). Immu-
noprecipitates were normalized to equal trichloroacetic acid-
precipitable 35S-labeled protein. The immunoprecipitates were
washed five times with NP-40 wash buffer (50 mM Tris–HCl
[pH 7.4], 0.5% NP-40, 5 mM EDTA, 150 mM NaCl) and
subjected to sodium dodecyl sulfate–polyacrylamide gel
electrophoresis (SDS–PAGE). Leupeptin (EMD Biosciences,
Inc.) was added to the pulse and chase medium at 200 μM final
concentration and Folimycin (Concanamycin A)(EMD Bios-
ciences, Inc.) was added to the pulse and chase medium at
20 nM final concentration. In some experiments, peptide:N-
Glycosidase F (PNGase F) (New England Biolabs, Beverly,
MA) was added to the immunoprecipitates according to the
manufacturer's instructions.
Immunoblots
Cell lysates (as described above) were assayed for protein
concentration using the Pierce BCA protein assay kit (Pierce,
Rockford, IL). The specified amounts of protein were subjected
to SDS–PAGE. The gels were transferred to BA-85 nitrocellu-
lose membrane (Whatman, Florham Park, NJ), and probed with
the α-HA mAb HA.11 (Covance), followed by goat α-mouse
HRP-conjugated secondary Ab (Bio-Rad, Hercules, CA).
Bands were visualized using the Pierce Supersubstrate Chemi-
luminescence reagents (Pierce) and in some cases quantitated
with an Alpha Imager (AlphaInnotech, San Leandro, CA).
Immunofluorescence microscopy
Cells on coverslips were washed with PBS and fixed with
4% paraformaldehyde for 20 min, permeabilized with 0.5%
saponin in PBS and 3% BSA, incubated with primary
antibodies for 30 min, washed, and followed by Alexa 488-
or Alexa 594-conjugated secondary antibodies.
Flow cytometry
Cells were removed from the plates with trypsin, washed
with ice-cold PBS, incubated with PE anti-HLA-A,B,C for
30 min on ice, washed thoroughly, and resuspended in ice-
cold PBS. Cell surface expression of class l MHC molecules
was then evaluated with a Beckman FACScalibur flow
cytometer.
Cloning of U21 from HHV-6A and -6B-infected cells
The J-JHAN T cell line was infected with strain U1102 of
HHV-6A, and the Molt-3 T cell line with strain Z29 of HHV-6B,
and genomic DNA was purified from infected cells. PCRamplification of both U21 DNAs was performed from the
gDNA, which yielded PCR products of the predicted sizes. The
resulting PCR products were cloned into the vector pCR-TOPO
(Invitrogen, Carlsbad, CA), and the sequences were confirmed.
PCR was performed from the cDNAs using the following
primers corresponding to the 5′ and 3′ ends of the HHV-6A
and -6B U21 open reading frames: -6A U21 (for C-terminally
HA-tagged construct), 5′-gccaccATGATGATCTGCCTT-3′
and 5′-TCAAATTTTTAATTCACGTCG-3′; -6A U21 (for
C-terminally SBPHA-tagged construct), 5′-gccaccATGAT-
GATCTGCCTT-3′ and 5′-CTCCTTCAGTCCTACAAAACA-
GGAAATACC-3′; -6B U21 (for C-terminally SBPHA-tagged
construct), 5′-gccaccATGAGCGCTTTGTTTATTAC-3′ and 5′-
CTCCTTCAGTCCTACAAAACAGGAAATACC-3′. The U21
cDNAs were then subcloned into the lentiviral expression
vector pHAGE, which was the generous gift from Drs. Gustavo
Mostoslavsky and Richard Mulligan (Harvard Medical School,
Boston, MA). C-terminally HA-tagged HHV-6A U21 was
amplified using a primer containing the additional HA
sequence: GCCTACCCATACGACGTACCAGACTACGCA.
C-terminally SBPHA-tagged -6A and -6B U21 were amplified
from primers containing the additional peptide tag sequence
(single letter code): SBP (DEKTTGWRGGHVVEGLAGE-
LEQLRARLEHHPQGQREP); TEV peptide (ENLY); and HA
peptide (YPYDVPDYA), as described in (Call et al., 2002).
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